Whereas ERBB3 mutations are more frequent in other tumor types (~11% in colon and gastric cancers, and ~6% in bladder and small bowel cancer)157,158, they rarely occur in lung cancer (1%–2%), and the prevalence is potentially higher in some NSCLC subsets e.g., squamous cell carcinoma159,160. This evidence concerns the gene ERBB3 and neoplasm.